Crinetics Pharmaceuticals (NASDAQ:CRNX) Upgraded at Wall Street Zen

Crinetics Pharmaceuticals (NASDAQ:CRNX) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

CRNX has been the subject of several other research reports. Lifesci Capital raised shares of Crinetics Pharmaceuticals to a “strong-buy” rating in a report on Friday, February 13th. The Goldman Sachs Group raised shares of Crinetics Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $67.00 target price for the company in a research note on Monday, January 12th. Citizens Jmp decreased their target price on shares of Crinetics Pharmaceuticals from $108.00 to $105.00 and set a “market outperform” rating for the company in a research report on Thursday, January 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a report on Wednesday, January 21st. Finally, Morgan Stanley raised their target price on Crinetics Pharmaceuticals from $77.00 to $80.00 and gave the company an “overweight” rating in a research report on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $75.78.

Crinetics Pharmaceuticals Stock Down 6.0%

Shares of NASDAQ CRNX opened at $41.10 on Friday. The firm’s 50-day moving average price is $48.83 and its two-hundred day moving average price is $43.11. Crinetics Pharmaceuticals has a 52-week low of $24.10 and a 52-week high of $57.99. The stock has a market capitalization of $4.20 billion, a P/E ratio of -8.32 and a beta of 0.19.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($1.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.08. The business had revenue of $3.89 million for the quarter, compared to analysts’ expectations of $4.32 million. Crinetics Pharmaceuticals had a negative return on equity of 39.91% and a negative net margin of 6,046.22%.The business’s quarterly revenue was up NaN% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.88) EPS. As a group, equities research analysts expect that Crinetics Pharmaceuticals will post -3.73 earnings per share for the current year.

Insider Buying and Selling

In other Crinetics Pharmaceuticals news, insider Isabel Kalofonos sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $55.00, for a total value of $137,500.00. Following the completion of the sale, the insider directly owned 834 shares in the company, valued at $45,870. This represents a 74.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.60% of the stock is currently owned by insiders.

Institutional Trading of Crinetics Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Smartleaf Asset Management LLC grew its holdings in Crinetics Pharmaceuticals by 107.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 639 shares of the company’s stock worth $30,000 after acquiring an additional 331 shares during the period. Headlands Technologies LLC acquired a new stake in Crinetics Pharmaceuticals in the 2nd quarter valued at about $30,000. Farther Finance Advisors LLC boosted its position in shares of Crinetics Pharmaceuticals by 523.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 842 shares of the company’s stock valued at $35,000 after purchasing an additional 707 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Crinetics Pharmaceuticals in the 2nd quarter worth approximately $45,000. Finally, Penserra Capital Management LLC acquired a new position in shares of Crinetics Pharmaceuticals in the 2nd quarter worth approximately $48,000. Institutional investors and hedge funds own 98.51% of the company’s stock.

Key Headlines Impacting Crinetics Pharmaceuticals

Here are the key news stories impacting Crinetics Pharmaceuticals this week:

• Positive Sentiment: Q4 EPS beat consensus: Crinetics reported a narrower-than-expected loss (GAAP EPS of -$1.29 vs. the -$1.37 consensus), which can be viewed as a modest positive on execution vs. expectations. MarketBeat Earnings Summary
• Positive Sentiment: Management emphasized product launch momentum and provided a business update on the earnings call, signaling commercial progress that could support future revenue growth if sustained. Earnings Call Highlights
• Neutral Sentiment: Full earnings materials and transcripts published — investors can review the call transcript and slides for detail on guidance, launch metrics and timing. Seeking Alpha Transcript Slide Deck
• Neutral Sentiment: Reported short-interest data in system appears inconclusive/zeroed out for February (no actionable increase). This entry likely has no material impact until validated by official exchanges.
• Negative Sentiment: Revenue missed Street expectations (reported ~$3.9M vs. ~$4.3M consensus) and the company’s quarterly loss widened year-over-year — a revenue shortfall and rising losses can pressure sentiment, especially for a company transitioning to commercial sales. Zacks Earnings Note
• Negative Sentiment: Analysts and commentators flagged a new shelf/ESOP registration alongside discussion of product launch momentum — while the shelf can enable capital raises and fund commercialization, it also raises near-term dilution concerns that can hurt the share price. Yahoo Analysis

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.